Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-057855
Filing Date
2025-06-09
Accepted
2025-06-09 16:31:39
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 11452
  Complete submission text file 0001104659-25-057855.txt   13448
Mailing Address 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237
Business Address 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237 (720) 437-6580
AYTU BIOPHARMA, INC (Subject) CIK: 0001385818 (see all company filings)

EIN.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-88813 | Film No.: 251034568
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 130 MAIN ST. 2ND FLOOR NEW CANAAN CT 06840
Business Address 130 MAIN ST. 2ND FLOOR NEW CANAAN CT 06840 203-404-1172
Nantahala Capital Management, LLC (Filed by) CIK: 0001472322 (see all company filings)

EIN.: 201151760 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13D/A